Thermo Fisher Scientific (NYSE:TMO) shares are trading higher on Wednesday after the company inked a deal to acquire Clario Holdings for $8.875 billion in cash, plus potential future earnout and other performance-based payments.

• TMO stock is moving in positive territory. Track the latest developments here.

The Details

Notably, Clario centralizes clinical trial endpoint data from devices, sites and patients, allowing pharma and biotech companies to digitally collect, manage, and analyze evidence across all phases of drug development, supporting faster and more confident trial decisions.

Its platform has contributed to roughly 70% of FDA drug approvals over the past decade.

Notably, Clario is projected to generate around $1.25 ...